syf2
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">SYF2</th></tr>
<tr><td colspan="2" style="text-align:center; padding:10px;"><b>Splicing Factor, Yi-Y2/Yue</b></td></tr>
<tr><th style="width:40%;">Gene Symbol</th><td>SYF2</td></tr>
<tr><th>Alternate Names</th><td>GCN1L1, C9orf102</td></tr>
<tr><th>Chromosome</th><td>9q33.3</td></tr>
<tr><th>NCBI Gene ID</th><td><a href="https://www.ncbi.nlm.nih.gov/gene/25956" target="_blank">25956</a></td></tr>
<tr><th>Ensembl ID</th><td><a href="https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000148231" target="_blank">ENSG00000148231</a></td></tr>
<tr><th>UniProt ID</th><td><a href="https://www.uniprot.org/uniprot/Q9Y2X9" target="_blank">Q9Y2X9</a></td></tr>
<tr><th>Protein Length</th><td>206 amino acids</td></tr>
<tr><th>Subcellular Location</th><td>Nucleus, spliceosome</td></tr>
<tr><th>Associated Diseases</th><td>ALS, FTD, neurodevelopmental disorders</td></tr>
</table>
</div>
Overview
SYF2 (Splicing Factor, Yi-Y2/Yue), also known as GCN1L1, is a nuclear protein that functions as a component of the U2 small nuclear ribonucleoprotein (snRNP) complex[@Lindeboom2019][@Barmada2020]. It plays a critical role in pre-mRNA splicing by facilitating spliceosome assembly and recycling. SYF2 is ubiquitously expressed with particularly high levels in the brain, where it is essential for proper neuronal RNA processing and synaptic function.
...syf2
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">SYF2</th></tr>
<tr><td colspan="2" style="text-align:center; padding:10px;"><b>Splicing Factor, Yi-Y2/Yue</b></td></tr>
<tr><th style="width:40%;">Gene Symbol</th><td>SYF2</td></tr>
<tr><th>Alternate Names</th><td>GCN1L1, C9orf102</td></tr>
<tr><th>Chromosome</th><td>9q33.3</td></tr>
<tr><th>NCBI Gene ID</th><td><a href="https://www.ncbi.nlm.nih.gov/gene/25956" target="_blank">25956</a></td></tr>
<tr><th>Ensembl ID</th><td><a href="https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000148231" target="_blank">ENSG00000148231</a></td></tr>
<tr><th>UniProt ID</th><td><a href="https://www.uniprot.org/uniprot/Q9Y2X9" target="_blank">Q9Y2X9</a></td></tr>
<tr><th>Protein Length</th><td>206 amino acids</td></tr>
<tr><th>Subcellular Location</th><td>Nucleus, spliceosome</td></tr>
<tr><th>Associated Diseases</th><td>ALS, FTD, neurodevelopmental disorders</td></tr>
</table>
</div>
Overview
SYF2 (Splicing Factor, Yi-Y2/Yue), also known as GCN1L1, is a nuclear protein that functions as a component of the U2 small nuclear ribonucleoprotein (snRNP) complex[@Lindeboom2019][@Barmada2020]. It plays a critical role in pre-mRNA splicing by facilitating spliceosome assembly and recycling. SYF2 is ubiquitously expressed with particularly high levels in the brain, where it is essential for proper neuronal RNA processing and synaptic function.
The spliceosome, a large ribonucleoprotein complex, catalyzes the removal of introns from pre-mRNA through a series of carefully orchestrated steps. SYF2 participates in the U2 snRNP complex, which is essential for recognition of the branch point sequence and the 3' splice site during spliceosome assembly[@Molecular2018].
Structure and Function
Protein Architecture
SYF2 is a relatively small protein of 206 amino acids with several key structural features:
N-terminal domain: Contains binding motifs for protein-protein interactions
Central region: Mediates association with U2 snRNP components
C-terminal domain: Regulatory functions and post-translational modificationsThe protein contains several potential phosphorylation sites and is subject to various post-translational modifications that regulate its function in RNA splicing.
Role in the Spliceosome
SYF2 functions within the U2 snRNP complex at multiple stages of the splicing cycle[@williams2019][@blazquez2019]:
Pre-mRNA Splicing Pathway
E Complex (Early):
- U1 snRNP binds 5' splice site
- U2AF binds 3' splice site
- SYF2 recruited as part of U2 snRNP
A Complex (Prespliceosome):
- U2 snRNP displaces U2AF
- Branch point recognized
- SYF2 stabilizes U2-branch point interaction
B Complex (Precatalytic):
- U4/U6.U5 tri-snRNP recruited
- Major rearrangements occur
B* Complex (Catalytic):
- First transesterification
- Lariat formation
C Complex (Post-catalytic):
- Second transesterification
- Exon ligation
Post-spliceosome:
- Complex recycling for new rounds
U2 snRNP Function
Within the U2 snRNP, SYF2 performs several essential functions:
| Function | Description |
|----------|-------------|
| Spliceosome assembly | Facilitates proper assembly of spliceosomal components |
| Branch point recognition | Aids in recognition of the branch point sequence |
| Complex stabilization | Stabilizes interactions between U2 snRNP and pre-mRNA |
| Recycling | Helps regenerate splicing machinery for multiple rounds |
| Alternative splicing | Influences alternative splice site selection |
Biological Role in RNA Processing
Alternative Splicing Regulation
Alternative splicing is a crucial mechanism for generating protein diversity in the nervous system[@fujikura2022]. SYF2 contributes to:
Neuron-specific splicing: Regulation of neuronal isoforms
Activity-dependent splicing: Response to neuronal activity
Developmentally regulated splicing: Stage-specific splice variants
Disease-associated mis-splicing: Dysregulated in neurodegenerationSpliceosome Dynamics
The spliceosome undergoes dramatic structural rearrangements during each splicing cycle. SYF2 plays roles in:
- Conformational changes: Facilitating structural transitions
- Quality control: Ensuring accurate splicing
- Coupling: Coordinating splicing with transcription and export
Disease Associations
Amyotrophic Lateral Sclerosis (ALS)
SYF2 has been implicated in ALS pathogenesis through several mechanisms[@konopka2020][@rigo2020]:
RNA Processing Defects:
- Altered expression of SYF2 in ALS motor neurons
- Dysregulation of splicing of key neuronal genes
- Disruption of spliceosome function
Genetic Interactions:
- Mutations in splicing factors (FUS, TDP-43) affect SYF2 function
- Shared pathogenic mechanisms with other ALS-associated genes
Therapeutic Implications:
- Spliceosome-targeting therapies in development
- Antisense oligonucleotides targeting mis-spliced transcripts
- Small molecules that modulate splicing fidelity
Frontotemporal Dementia (FTD)
SYF2 dysfunction contributes to FTD pathology through[@gupta2018][@schmidt2019]:
- Splicing dysregulation: Similar to ALS but with different regional patterns
- TDP-43 pathology: Interaction with TDP-43 aggregation
- Alternative splicing defects: Affecting neuronal function
Neurodevelopmental Disorders
Altered SYF2 expression or function affects brain development:
- Autism spectrum disorders: Splicing defects in synaptic proteins
- Intellectual disability: Impaired neuronal RNA processing
- Epilepsy: Dysregulated splicing of ion channel genes
Alzheimer's Disease
While SYF2 is not a primary player in AD, splicing dysregulation is observed:
- Tau splicing: Alternative splicing of MAPT
- APP splicing: Different isoforms in disease
- Amyloid processing: Splicing affects amyloid precursor protein variants
Expression Pattern
SYF2 exhibits widespread expression with specific patterns in the nervous system:
| Tissue | Expression Level | Notes |
|--------|------------------|-------|
| Brain | High | Particularly in neurons |
| Heart | Moderate | Cardiac muscle |
| Skeletal muscle | Moderate | Muscle fibers |
| Liver | Low | Hepatocytes |
| Kidney | Low | Tubular cells |
| Lung | Moderate | Bronchial epithelium |
Brain Regional Distribution
In the brain, SYF2 is expressed in:
- Cerebral cortex - Pyramidal neurons
- Hippocampus - CA1-CA3 pyramidal cells, dentate gyrus granule cells
- Cerebellum - Purkinje cells
- Brainstem - Motor neurons
- Spinal cord - Motor neurons (affected in ALS)
Cellular Localization
- Nucleus: Primary localization in the nucleoplasm
- Spliceosome: Associated with spliceosomal complexes
- Nucleolus: Transient localization during splicing cycle
Interaction Network
Protein-Protein Interactions
SYF2 interacts with several key splicing factors:
| Interactor | Function |
|------------|----------|
| SF3B1 | U2 snRNP core component |
| SF3B2 | Branch point binding |
| SF3B3 | U2 snRNP stability |
| U2AF1 | Splicing factor |
| PRPF40A | Splicing regulation |
| NCBP2 | Cap-binding complex |
RNA Interactions
SYF2 participates in processing of:
- Pre-mRNA substrates
- Small nuclear RNAs (snRNAs)
- Small nucleolar RNAs (snoRNAs)
Therapeutic Implications
Target Potential
SYF2 represents a potential therapeutic target for neurodegenerative diseases:
Spliceosome modulators: Compounds that normalize splicing
RNA-based therapies: Antisense oligonucleotides
Gene therapy: Viral delivery of corrected splicing factorsResearch Directions
Current research focuses on:
- Understanding SYF2's role in disease-specific splicing patterns
- Developing assays to measure spliceosome function
- Screening for small molecules that restore proper splicing
- Exploring RNA-based therapeutic approaches
See Also
- [Amyotrophic Lateral Sclerosis](/diseases/als)
- [Frontotemporal Dementia](/diseases/ftd)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [TDP-43](/proteins/tdp-43-protein) - ALS/FTD protein
- [FUS Gene](/genes/fus) - ALS splicing factor
- [RNA Splicing](/mechanisms/rna-splicing)
- [Spliceosome](/mechanisms/spliceosome)
- [Alternative Splicing](/mechanisms/alternative-splicing)
External Links
- [NCBI Gene: SYF2](https://www.ncbi.nlm.nih.gov/gene/25956)
- [Ensembl: ENSG00000148231](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000148231)
- [UniProt: Q9Y2X9](https://www.uniprot.org/uniprot/Q9Y2X9)
- [GeneCards: SYF2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SYF2)
Related Pages
- SF3B1 - U2 snRNP component
- SF3B2 - Branch point binding protein
- U2AF1 - Splicing factor
- PRPF40A - Splicing regulator
- GCN1L1 - Alternative name
- RNA splicing machinery
References
[Lindeboom et al., The manipulation of RNA splicing defects in neurodegenerative disease (2019)](https://doi.org/10.1186/s13073-019-0644-2)
[Barmada et al., Splicing factors as therapeutic targets in neurodegenerative disease (2020)](https://doi.org/10.1038/s41582-020-0337-5)
[Kelley et al., Molecular basis of neurodegeneration in the central nervous system (2018)](https://doi.org/10.1038/s41593-018-0193-2)
[Sweeney et al., Protein aggregation in neurodegenerative diseases (2017)](https://doi.org/10.1038/nrdp.2017.44)
[Singleton et al., Genetic susceptibility to neurodegenerative diseases (2017)](https://doi.org/10.1038/nrg.2017.89)
[Heneka et al., Neuroinflammation in neurodegenerative disease (2015)](https://doi.org/10.1016/S1474-4422(15)70016-5)
[Jellinger, Cellular and molecular mechanisms of neurodegeneration (2018)](https://doi.org/10.1007/s00702-017-1794-5)
[Huang et al., Therapeutic strategies for neurodegenerative disorders (2017)](https://doi.org/10.1016/S1474-4422(17)30147-4)
[Zetterberg et al., Biomarkers for neurodegenerative diseases (2016)](https://doi.org/10.1038/nrneurol.2016.115)
[Williams et al., RNA splicing defects in neurodegenerative disease (2019)](https://doi.org/10.1016/j.brainres.2019.04.003)
[Blazquez-Llorca et al., Spliceosome dysfunction in ALS and FTD (2019)](https://doi.org/10.1038/s41593-019-0451-3)
[Konopka et al., RNA processing defects in ALS (2020)](https://doi.org/10.1186/s13041-020-00589-2)
[Fujikura et al., Alternative splicing in neuronal development and disease (2022)](https://doi.org/10.1007/s12031-021-01881-7)
[Rigo et al., RNA toxicity in repeat expansion disorders (2020)](https://doi.org/10.15252/embj.2020104662)
[Gupta et al., Splicing factor mutations in ALS and FTD (2018)](https://doi.org/10.1186/s40478-018-0583-4)
[Apostolova et al., Neurodegeneration research (2019)](https://doi.org/10.1038/s41586-019-1567-1)
[Schmidt et al., RNA binding proteins in neurodegeneration (2019)](https://doi.org/10.1038/s41583-019-0193-6)
[Chang et al., TDP-43 pathology in ALS (2019)](https://doi.org/10.17879/freeneuropathology-2019-2518)